GLG LLC’s Adamas Pharmaceuticals ADMS Stock Holding History

GLG LLC’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-47,900	Closed	-$1.01M	–	512
2017 Q3	$1.01M	Buy	+47,900	New	+$878K	0.07%	292

Other funds holding ADMS

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BWCA

Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

GLG LLC's ADMS Position: Q4 2017 in Review

GLG LLC sold out of Adamas Pharmaceuticals (ADMS) in Q4 2017, closing a stake of 47,900 shares — an estimated $1.01M sold.

GLG LLC first reported a position in ADMS in Q3 2017 and held it in 1 quarter. The position peaked at $1.01M in Q3 2017. 117 funds tracked by Wall St. Rank hold ADMS as of Q4 2017.

GLG LLC reported no remaining Adamas Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
GLG LLC sold 47,900 Adamas Pharmaceuticals shares in Q4 2017, an estimated $1.01M.
GLG LLC first reported a position in Adamas Pharmaceuticals in Q3 2017 and held it in 1 quarter.
GLG LLC's Adamas Pharmaceuticals position peaked at $1.01M in Q3 2017.
117 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2017.

Based on GLG LLC's 13F filing for Q4 2017, filed 14 Feb 2018.